Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02506959 · ClinicalTrials.gov registry record · Phase 2
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT02506959: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02506959 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02506959, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving high-dose chemotherapy, such as gemcitabine hydrochloride, busulfan, and melphalan, before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Previously collected stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
Interventions
- DRUG Melphalan
- DRUG Busulfan
- DRUG Gemcitabine Hydrochloride
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2015-09-14 |
| Est. Completion | 2024-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02506959
The ClinicalTrials.gov registry entry for NCT02506959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT02506959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02506959 about?
NCT02506959 is a clinical study titled "Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma". This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cel...
What is the current status of trial NCT02506959?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2015-09-14. Estimated completion is 2024-06-03.
What interventions are being tested in trial NCT02506959?
The interventions under investigation include: Melphalan (DRUG), Busulfan (DRUG), Gemcitabine Hydrochloride (DRUG), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE), Panobinostat (DRUG).
Who is sponsoring clinical trial NCT02506959?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.